LIVE
COURSES
2015
September 8–12, 2015
ACC Cardiovascular Board
Review for Certification
and Recertification
The Swissotel
Chicago, IL
September 12, 2015
The ACC Cardiovascular
Board Review for Certification
and Recertification MOC
Study Session
The Swissotel
Chicago, IL
September 17, 2015
Team Based Care and
Transformation of Care –
Webinar
Corlanor (ivabradine)
BRIEF SUMMARY OF PRESCRIBING INFORMATION
Please see package insert for full Prescribing Information
1. INDICATIONS AND USAGE
Corlanor is indicated to reduce the risk of hospitalization for
worsening heart failure in patients with stable, symptomatic
chronic heart failure with left ventricular ejection fraction
≤ 35%, who are in sinus rhythm with resting heart rate ≥ 70
beats per minute and either are on maximally tolerated doses
of beta-blockers or have a contraindication to beta-blocker use.
4. CONTRAINDICATIONS
Corlanor is contraindicated in patients with:
• Acute decompensated heart failure
• Blood pressure less than 90/50 mmHg
• Sick sinus syndrome, sinoatrial block, or 3rd degree AV block,
unless a functioning demand pacemaker is present
• Resting heart rate less than 60 bpm prior to treatment [see
Warnings and Precautions (5.3)]
• Severe hepatic impairment [see Use in Specific Populations
(8.6)]
• Pacemaker dep V